Patient 2. A 21-year-old male patient was first admitted at age 13 because of isolated swelling and pain in the knees. This was diagnosed as oligoarticular JIA and treated with local steroid injections, and afterward with NSAID and SSZ because of persisting arthritis. Arthroscopy with biopsy and synovial fluid analysis confirmed nonspecific chronic synovitis. In the following years, the extension of the disease to the wrists, hips, ankles, and spine led to the use of MTX (15 mg/m 2 /week) and NSAID (diclofenac 2 mg/kg/day), with low efficacy. At age 18, the patient started to develop severe aplastic anemia, requiring multiple transfusions, and thrombocytopenia, progressively associated with mild leukopenia (Figure 1 ). Bone marrow examination showed hypocellularity (< 5% to 40%), trilinear hematopoiesis with dyserythropoiesis, and moderate reticular fibrosis. Maintenance therapy of prednisone (PRED) 35 mg/day was started and then gradually tapered. Hyperhidrosis and thickening of the skin with cutis verticis gyrata and seborrhea also became increasingly evident (Supplementary Figure 3 available online at jrheum.org). No digital clubbing was observed. PHO was suspected, and elevated PGE2 ( Supplementary Table 1 available online at jrheum.org) and DNA sequencing confirmed this diagnosis. Compound heterozygosity for 2 nonsense mutations in SLCO2A1 was found: c.754C>T (p.R252X), previously described 9 , and c.794C>G (p.S265X), which was novel (Table 1 ; Supplementary Figure 3 available online at jrheum.org). The patient continued receiving ibuprofen 400 mg 3 times per day, combined with low-dose steroid therapy (PRED 10 mg/day) for myelofibrosis. The hematological picture improved dramatically, achieving complete normalization. The patient had no further joint relapses, but followup radiographs of the hands, knees, and ankles showed metacarpal and fibular bilateral periostosis ( Supplementary Figure 4 available online at jrheum.org). Generalized hyperhidrosis required oxybutynin 2.5 mg 3 times per day, with great efficacy. Considering the stabilization of the rheumatological and hematological picture, and the risk of worsening thrombocytopenia, NSAID were stopped and used again only in the last year for episodes of back pain.
Patient 3.
A 15-year-old girl was first evaluated at the age of 9 for arthralgias in the knees, back, and ankles. She also had hyperhidrosis and a history of delayed suture closure. Over time, more pronounced coarse facial features developed. At 11 years old, she had signs of active arthritis in the knees, hands, hips, and feet, with normal laboratory tests and radiographs. Only magnetic resonance imaging (MRI) showed chronic arthritis in the left wrist. Therapy with NSAID (indomethacin 1 mg/kg/day) was started, with remarkable improvement of joint involvement and pain relief. At 15 years old, the patient relapsed with arthritis of the knees, associated for the first time with digital clubbing, hyperhidrosis, and mild anemia. A brief period of MTX (15 mg/m 2 /week) was tried with no effect. PHO was diagnosed through the genetic testing of HPGD, identifying the homozygous c.120delA mutation (Table 1) . Indomethacin was doubled with significant clinical improvement, both in the joint and skin involvement. The dysmorphic features did not progress.
Patient 4. This male child was evaluated at the age of 2.5 years after preterm birth (33 + 4 weeks, birth weight 1700 g) for swelling and stiffness of the knees, gradually followed by involvement of the ankles, toes, and hands. Throughout the course of his disease, he had required surgery for a patent ductus arteriosus and physical therapy, including helmet remodeling, in the first months of his life for brachy-plagiocephaly. Delayed suture closure and late motor development and speech/language were observed. Physical examination also identified hyperhidrosis of the hands. Blood tests including antinuclear antibody, rheumatoid factor and inflammatory markers, ultrasound scan of the skull, and MRI of the knees were normal. Treatment with NSAID (ibuprofen 20 mg/kg/day) was started with positive results. At 3 years, bony enlargement of the distal phalanges and a thickened skull were revealed by radiographs. At age 4, PHO was diagnosed by the identification of 2 compound heterozygous HPGD mutations: c.175_176delCT and the novel c.298T>C (p.W100R; Table 1 ; Supplementary Data and Supplementary Figure 5 available online at jrheum.org). The patient was treated with ibuprofen, initially at 20 mg/kg/day and subsequently as necessary, with a stable clinical pattern requiring therapy around 2-3 times a week.
Here we have described 4 patients with PHO/PDP with HPGD or SLCO2A1 deficiency [OMIM#259100, autosomal recessive primary hypertrophic osteoarthropathy (PHOAR) 1 and #614441, PHOAR2, respectively].
Although mutations in either HPGD or SLCO2A1 cause PHO/PDP, there are phenotypic differences associated with each gene exemplified in patients 1 and 2, who had mutations in HPGD and SLCO2A1, respectively. Patient 1 developed initial symptoms much earlier than patient 2. The onset of PHO is usually before the age of 20, but its biphasic incidence is now attributed to the genetic heterogeneity, with onset of symptoms in early childhood for HPGD patients and during puberty/early adulthood for SLCO2A1 patients 5, 6, 9, 10, 11, 12, 13 .
Patients with SLCO2A1 mutations, such as patient 2, have been described as having more severe symptoms overall 6, 9, 11 , the presence of skin folds (as cutis verticis gyrata) 5, 12 , and chronic anemia and/or pancytopenia, secondary to hypocellular myelofibrosis 5, 14, 15 . On the other hand, patients 3 and 4 exhibited delayed cranial suture closure that has led to the use of the term "cranio-osteoarthropathy". This has only been seen in patients with HPGD mutations 2, 4, 12, 16 .
The histories of our patients suggest approaches for clinical practice. For example, young children with swollen and painful joints and a history of patent ductus arteriosus, delayed closure of the cranial sutures, and fontanelles or Wormian bones should be investigated immediately for PHO because clubbing, periostosis, and skin changes might be absent. When PHO/PDP is suspected, secondary causes have to be excluded. Blood and
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Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved. x ADA x early morning urine can be considered for prostaglandin measurement, but their detection is not feasible in all laboratories, and implications in differential diagnosis, followup, and treatment still need to be studied and standardized with age-related values 13 . In contrast, sequence analysis of both genes is simple and cheap, and therefore should be considered as an early investigation when PHO/PDP is suspected because it can provide confirmation of diagnosis. The presence of chronic arthritis often leads to a diagnosis of JIA. Nevertheless, a patient with JIA, nonresponder to DMARD and biological therapies, and with a better response to NSAID, should be considered as having another disease and investigated for further clinical signs. Indeed, HPGD and SLCO2A1 patients usually experience some positive effects on joint pain and swelling while being treated with NSAID 5, 12, 16, 17, 18 , but it is uncertain if either the use of indomethacin compared with ibuprofen could provide better results clinically, as for patient 3, or if the phenotype of this patient is milder as a consequence of being female.
Myelofibrosis is a life-threatening complication; consequently, when germline SLCO2A1 mutations are detected, the patient should be followed up periodically for myelofibrosis. The use of steroids can produce hemato-logical improvement, but no effects on skin or digital clubbing, and longer-term treatment may help in symptom stabilization 19 . NSAID appear to be the best option for treatment, while other treatments can be evaluated individually, but support for their use is largely anecdotal 20, 21, 22 .
